The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

INTRODUCTION: Nintedanib can inhibit processes involved in the progression of fibrosis and can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic-interstitial lung disease (fibrotic-ILDs). Although the adverse events associated with nintedan...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chao-Hsien, Lin, Hui-Chuan, Wang, Ya-Hui, Wang, Cheng-Yi, Lin, You Shuei, Lai, Chih-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121296/
https://www.ncbi.nlm.nih.gov/pubmed/33989328
http://dx.doi.org/10.1371/journal.pone.0251636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121296/
https://www.ncbi.nlm.nih.gov/pubmed/33989328
http://dx.doi.org/10.1371/journal.pone.0251636

Ejemplares similares